Last update 22 Jun 2024

Cefdinir

Last update 22 Jun 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryCefdinir, marketed under the brand name Omnicef, is a small molecule drug that acts as a penicillin-binding protein (PBP) inhibitor and a cell wall inhibitor. It is indicated for the treatment and prevention of infections caused by susceptible bacteria. Cefdinir works by inhibiting the growth and multiplication of bacteria that cause infections, including streptococcus, staphylococcus, and Haemophilus influenzae. It is approved in several countries, including the US, China, Japan, and South Korea. Omnicef is available as capsules or an oral suspension and is typically administered once or twice daily depending on the severity of the infection. It is important to use this medication only for the treatment or prevention of bacterial infections, as overuse or misuse can lead to the development of drug-resistant bacteria.

Drug Type

Small molecule drug

Synonyms

Cefdinir (JP17/USP/INN), Cefzon Capsule, CFDN

+ [17]

Target

PBPs

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors

Therapeutic Areas

Infectious DiseasesMouth and Tooth DiseasesOtorhinolaryngologic Diseases+ [3]

Active Indication

BronchitisCystitisOtitis Media+ [8]

Inactive Indication

Acute BronchitisAcute maxillary sinusitisAcute otitis media+ [24]

Originator Organization

Astellas Pharma, Inc.

Active Organization

LTL Pharma Co., Ltd.

Pfizer Inc.

Astellas Pharma, Inc.

+ [3]

Inactive Organization

Shenzhen Zhijun Pharmaceutical Trade Co., Ltd.

AbbVie, Inc.

Abbott Laboratories

Drug Highest PhaseApproved

First Approval Date

(01 Jan 1991),

Gram-Negative Bacterial InfectionsGram-Positive Bacterial Infections

RegulationPriority Review (CN)

Structure

Molecular FormulaC14H13N5O5S2

InChIKeyRTXOFQZKPXMALH-GHXIOONMSA-N

CAS Registry91832-40-5

Clinical Trials associated with Cefdinir

NCT06406114 / Not yet recruitingPhase 2

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.

Start Date01 Aug 2024

Sponsor / Collaborator

The General Hospital Corp.

[+1]

CTR20241822 / RecruitingNot Applicable

头孢地尼颗粒在健康受试者中单中心、随机、开放、两制剂、单剂量、双周期、双交叉空腹和餐后状态下的生物等效性试验

[Translation] A single-center, randomized, open-label, two-dose, single-dose, two-period, double-crossover bioequivalence study of cefdinir granules in healthy subjects under fasting and fed conditions

本研究考察健康受试者在空腹及餐后条件下，单次口服由康普药业股份有限公司生产的头孢地尼颗粒（受试制剂，规格：50mg）与相同条件下单次口服由LTLファーマ株式会社持证的头孢地尼细粒剂（参比制剂，商品名：Cefzon®，规格：50mg/0.5g）的药动学特征，评价两制剂间的生物等效性及安全性，为该受试制剂的注册申请提供依据。

[Translation]

This study investigated the pharmacokinetic characteristics of a single oral administration of cefdinir granules (test preparation, specification: 50 mg) produced by Compu Pharmaceutical Co., Ltd. and a single oral administration of cefdinir fine granules (reference preparation, trade name: Cefzon®, specification: 50 mg/0.5 g) certified by LTL Pharmaceutical Co., Ltd. under the same conditions in healthy subjects under fasting and postprandial conditions, evaluated the bioequivalence and safety of the two preparations, and provided a basis for the registration application of the test preparation.

Start Date18 May 2024

Sponsor / Collaborator

Hunan Kangpu Pharmaceutical Co. Ltd.

CTR20241322 / RecruitingNot Applicable

中国健康受试者空腹和餐后单次口服头孢地尼干混悬剂的随机、开放、两序列、两周期、双交叉设计的生物等效性试验

[Translation] A randomized, open-label, two-sequence, two-period, double-crossover bioequivalence study of a single oral dose of cefdinir dry suspension in Chinese healthy volunteers on an empty stomach or after a meal

主要研究目的研究空腹和餐后状态下单次口服受试制剂头孢地尼干混悬剂（规格：250mg/5ml，广东金城金素制药有限公司提供）与参比制剂头孢地尼干混悬剂（规格：250mg/5ml，持证商：Aurobindo Pharma Limited），在健康成年受试者体内的药代动力学，评价空腹和餐后口服两种制剂的生物等效性。次要研究目的评价中国健康受试者空腹和餐后状态下，单次口服受试制剂头孢地尼干混悬剂和参比制剂头孢地尼干混悬剂后的安全性。

[Translation]

Main study objectives To study the pharmacokinetics of a single oral dose of the test preparation cefdinir dry suspension (specification: 250mg/5ml, provided by Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd.) and the reference preparation cefdinir dry suspension (specification: 250mg/5ml, licensee: Aurobindo Pharma Limited) in healthy adult subjects under fasting and fed conditions, and to evaluate the bioequivalence of the two preparations when taken orally under fasting and fed conditions. Secondary study objectives To evaluate the safety of a single oral dose of the test preparation cefdinir dry suspension and the reference preparation cefdinir dry suspension in healthy Chinese subjects under fasting and fed conditions.

Start Date06 May 2024

Sponsor / Collaborator

Guangdong Jincheng Jinsu Pharmaceutical Co Ltd.

100 Clinical Results associated with Cefdinir

100 Translational Medicine associated with Cefdinir

100 Patents (Medical) associated with Cefdinir

474

Literatures (Medical) associated with Cefdinir

04 Jan 2024·Journal of AOAC International

Optimization of a Solid-Phase Extraction Coupled with a High-Performance Liquid Chromatography and Diode Array Ultraviolet Detection Method for Monitoring of Different Antibiotic Class Residues in Water Samples

Article

Author: Abdel Salam, Randa A ; Mahmoud, Rania A ; Hadad, Ghada M ; Mokhtar, Hatem I

Abstract:

Background:

The increased use of cephalosporin antibiotics in the last few years as well as the detection of their residues in wastewater treatment plants and hospital wastewater poses a risk for infiltration of their residues into environmental water samples.

Objective:

A simplified, sensitive, and convenient solid-phase extraction (SPE) procedure coupled with either HPLC or fast HPLC methods with diode array detection was developed and validated to screen the residues of six different cephalosporin antibiotics: cefoperazone, cefipime, ceftazedime, ceftriaxone, cefdinir, and cefotaxime, along with amoxicillin, levofloxacin, and ciprofloxacin in water samples.

Methods:

An HPLC–diode array detector (HPLC–DAD) method and a fast HPLC method, based on a core-shell stationary phase, were developed for the fast screening of the antibiotic compounds. In addition, the SPE step was optimized to enable the extraction of the studied drugs with high accuracy of the recovered amounts of residues.

Results:

The method sensitivity was enhanced by the coupling of SPE with HPLC–DAD and fast HPLC to achieve low LODs; from 0.2 to 3.8 ng/mL and from 0.65 to 12.2 ng/mL, respectively. The developed methods were augmented by LC–MS/MS determination for confirmation of identity and quantity of any positively identified sample. The method was applied to the analysis of water samples collected from a rural site. In Addition, an example application of cleaning validation of cefotaxime-contaminated stainless-steel surfaces was provided.

Conclusion:

The method’s simplicity and high sensitivity encourage its application in monitoring of antibiotic residues in different types of water samples such as environmental samples and samples from cleaning validation activities.

Highlights:

HPLC–DAD and fast HPLC methods were developed for separation of nine different antibiotics. The combination with the SPE procedure achieved low detection limits; from 0.2 to 3.8 ng/mL for SPE–HPLC–DAD and from 0.65 to 12.2 ng/mL for SPE–fast HPLC.

01 Jan 2024·The Journal of arthroplasty

Should All Patients Receive Extended Oral Antibiotic Prophylaxis? Defining Its Role in Patients Undergoing Primary and Aseptic Revision Total Joint Arthroplasty

Article

Author: Karzon, Anthony L ; Tocio, Adam J ; Bundschuh, Kyle E ; Guild, George N ; Khawaja, Sameer R ; Heo, Kevin Y ; Muffly, Brian T ; Ayeni, Ayomide M ; Premkumar, Ajay

BACKGROUND:

Prior studies have demonstrated reduced periprosthetic joint infection (PJI) rates following extended oral antibiotics (EOAs) for high-risk patients undergoing primary total joint arthroplasty (TJA). This study compared 3-month PJI rates in all patients undergoing primary or aseptic revision TJA with or without EOA prophylaxis.

METHODS:

In total, 2,982 consecutive primary (n = 2,677) and aseptic revision (n = 305) TJAs were performed by a single, fellowship-trained arthroplasty surgeon from 2016 to 2022 were retrospectively reviewed. Beginning January 2020, all patients received 7 days of 300 mg oral cefdinir twice daily immediately postoperatively. Rates of PJI at 3 months were compared between patients who received or did not receive EOA.

RESULTS:

Rates of PJI at 3 months in patients undergoing primary and aseptic revision TJA were significantly lower in those receiving EOA prophylaxis compared to those who did not (0.41 versus 1.13%, respectively; P = .02). After primary TJA, lower PJI rates were observed with EOA prophylaxis utilization (0.23 versus 0.74%, P = .04; odds ratio [OR] 3.85). Following aseptic revision TJA, PJI rates trended toward a significant decrease with the EOA compared to without (1.88 versus 4.83%, respectively; P = .16; OR 2.71).

CONCLUSIONS:

All patients undergoing primary or aseptic revision TJA who received EOA prophylaxis were 3.85 and 2.71 times less likely, respectively, to develop PJI at 3 months compared to those without EOA. Future studies are needed to determine if these results are maintained at postoperative time periods beyond 3 months following primary TJA.

LEVEL OF EVIDENCE:

III, Retrospective review.

09 Dec 2023·Cureus

Acquired Thrombotic Thrombocytopenic Purpura in the Presence of a Urinary Tract Infection: A Rare Pediatric Case

Author: Cardenas, Jose M ; Joseph, Andrew M ; Karas, Monica ; Ahmad, Omama

Thrombotic thrombocytopenic purpura (TTP) is a type of microangiopathic hemolytic anemia that rarely presents in the pediatric population. This life-threatening disorder manifests as severe consumptive thrombocytopenia and disseminated micro-thromboemboli, leading to organ ischemia. Here, we present a case of an acute first-time episode of acquired TTP in a 17-year-old African American female with a past medical history of obesity, recurrent urinary tract infections, and dysfunctional uterine bleeding managed with oral contraceptives. The disorder's insidious onset was only preceded by a urinary tract infection managed as an outpatient with oral cefdinir for four days before symptoms worsened. The patient was admitted to the pediatric intensive care unit with microangiopathic hemolytic anemia, severe thrombocytopenia, low von Willebrand factor-cleaving protease (ADAMTS13) activity, hypofibrinogenemia, gross hematuria, and acute kidney injury. Further workup was significant for a positive urine culture for Escherichia coli. Her hospital course was complicated by an acute ischemic stroke. The patient's TTP was managed by five sessions of plasmapheresis (PLEX), two once-weekly doses of rituximab, five doses of caplacizumab, three doses of high-dose solumedrol, and six days of high-dose prednisone. This regimen led to an overall uptrend in platelet counts toward normal and resolved her kidney injury. Currently, the patient continues to recover as an outpatient with no disability, managed with rituximab and caplacizumab as relapse prophylaxis. This case highlights the need for further investigation into the consideration of TTP as part of the differential diagnosis for pediatric patients presenting with severe thrombocytopenia and acute kidney injury in the absence of a significant medical history. Additionally, the utilization of rituximab, caplacizumab, steroids, and PLEX for TTP in the pediatric population should be further investigated.

News (Medical) associated with Cefdinir

28 Aug 2023

·www.globenewswire.com

Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics. Ms. Filoon will oversee all company legal affairs including corporate governance and compliance functions. Dr. Kheoh will provide biostatistical leadership and strategic guidance into the development of the Company’s product candidate portfolio including the ongoing AMPLIFY-201 and AMPLIFY-7P trials of the lead asset, ELI-002. “Megan and Thian are joining us at an exciting time following our recent transition to a public company and as we continue to advance our lead clinical cancer vaccine candidate, ELI-002, for patients with mKRAS-driven cancers,” said Robert Connelly, Chief Executive Officer at Elicio Therapeutics. “Megan and Thian further strengthen an outstanding leadership team and their expertise will be invaluable in strengthening our legal and compliance functions, and processing data from our AMPLIFY trials, respectively.” Megan Filoon most recently served as the General Counsel and Corporate Secretary for Molecular Templates, Inc., a publicly traded, oncology-focused biotech, where she was responsible for providing legal counsel to the company’s board of directors and management team and advising on corporate governance, securities, employment, and real estate matters, among other areas. In this role, Ms. Filoon was responsible for managing the legal, human resources and administrative departments. She joined Molecular Templates as Corporate Counsel and during her time there, held roles of increasing responsibility, becoming General Counsel in February 2022. Prior to joining Molecular Templates, Ms. Filoon was a corporate associate at Blank Rome LLP, where she represented public and private companies in mergers and acquisitions, asset sales, securities offerings, business formation and corporate governance matters. She earned her Juris Doctor from Rutgers School of Law, where she was the Business Editor of the Rutgers Journal of Law and Public Policy, and her Bachelor of Arts in history and political science from Boston University. Thian Kheoh, Ph.D., has over 30 years of drug development and clinical trial experience in the biopharmaceutical industry. He most recently served as Vice President of Biometrics at Mirati Therapeutics where he led the Biometrics team in obtaining the FDA approval of KRAZATI® for KRAS G12C NSCLC patients. Prior to Mirati, he held roles of increasing responsibility at Tocagen, Janssen, Cougar Biotechnology, Biogen-Idec (now Biogen), TAP and Warner Lambert-Parke Davis. His work focused on exploring the application of statistical methodologies in preclinical and clinical studies, introducing novel statistical principles to trial design and strategic planning to bring effective drugs to cancer patients. Dr. Kheoh played an integral role in a number of successful global regulatory submissions and approvals of products that include ERLEADA®, DARZALEX®, OMNICEF®, SYLVANT®, VELCADE®, YONDELIS®, ZYTIGA® and the label expansion of RITUXAN®. Before joining the biopharmaceutical industry, he was an assistant professor at the University of Central Florida conducting research and providing lectures in Statistics. Dr. Kheoh earned his Ph.D. from the University of Western Ontario, Canada. About Elicio Therapeutics Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational Amphiphile (AMP) immunotherapies intended to precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers. Cautionary Note on Forward-Looking Statements Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding Elicio’s planned clinical programs and statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, and therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Elicio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to Elicio’s plans to research, develop and commercialize its current and future product candidates. New factors emerge from time to time, and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These risks are more fully discussed in the current report on Form 8-K that was filed with the SEC on June 2, 2023 and Elicio’s periodic reports and other documents filed from time to time with the SEC. Forward-looking statements included in this release are based on information available to Elicio as of the date of this release. Elicio does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this release, except to the extent required by law. Media ContactGloria GasaaturaLifeSci Communicationsggasaatura@lifescicomms.com646-970-4688 Investor Relations ContactHeather DiVecchiaElicio TherapeuticsIR@elicio.com857-209-0153

Executive ChangeImmunotherapyVaccineDrug Approval

30 Mar 2023

·www.sciencedaily.com

Study finds excess harm from commonly overprescribed antibiotics for patients resulting in widespread side effects

A new study finds that overprescribing and inappropriate prescribing of antibiotics is not only leading to antibiotic resistance, but also causing significant patient harm. It's one of the most comprehensive studies to document the impact of antibiotic overuse in clinical practice. When patients request or demand an antibiotic, even when it is unlikely to help, a physician might be tempted to give in and write a prescription, especially if they're working in a busy setting like an urgent care or emergency department. However, a major new study by researchers at Intermountain Health and Stanford University finds that overprescribing and inappropriate prescribing of antibiotics is not only leading to antibiotic resistance -- but also causing significant patient harm. It's one of the most comprehensive studies to document the impact of antibiotic overuse in clinical practice. Every year, there are enough outpatient antibiotics prescribed in the US to cover 80% of the population. The new study, published in the Journal of Internal Medicine, examined 51 million patient encounters over a 15-year-period and focused on upper respiratory infections where antibiotics were known to be overprescribed 50% of the time. Researchers found that some of the most dangerous antibiotics were rarely indicated and commonly used, leading to one in 300 of those patients experiencing side effects dire enough to require a follow up doctor's visit -- or even hospitalization. This study was one of the few studies large enough to estimate serious, but rare, adverse events such as a potentially deadly diarrheal infection, Clostridium difficile. With previous studies showing 34 Million unnecessary antibiotic prescriptions annually in the US, this translates to real harm for many patients and families. "These findings underscore that inappropriately giving patients antibiotics is causing real and widespread harm," said Harris Carmichael, MD, principal investigator of the study and hospitalist at Intermountain Health in Salt Lake City. "Having these kinds of side effects for one in a few hundred, or even a thousand, patients may not seem like a lot, but when you look at this problem on a population health level, we're talking about hundreds of thousands of adverse events severe enough that these patients needed additional care from a doctor." That means time off work and school for families, unnecessary doctor visits, and risks of serious infections that can last for months or years. In the retrospective study, researchers from Intermountain and Stanford reviewed insurance claims from the Clinformatics Data Mark Database. Using data from Medicare Advantage and commercial insurance patients in all 50 states, inpatient and outpatient administrative claims, pharmaceutical claims, and patient demographics for beneficiaries seen between December 2002 and December 2017, they found 50.9 million claims for upper respiratory infections, including sinusitis, pharyngitis, laryngitis, bronchitis and the common cold, representing 23 million unique patients. Researchers then identified instances when patients did and did not receive oral antibiotics for an upper respiratory infection, and if those patients were diagnosed with either diarrhea, candidiasis, Clostridium difficile infection or a mix of these side effects thereafter. They found that 62.4% of these upper respiratory infection patients filled a prescription for an antibiotic, consistent with prior studies of this population. Following their initial visits, 26% of those patients had a follow-up outpatient visit within 14 days. The odds of a patient being diagnosed with an adverse event increased 30% for those receiving antibiotics. Adverse events following antibiotics were found in as many as one in 300 prescriptions, depending on the antibiotic prescribed, or one in 1,150 prescriptions overall. "With millions of visits for upper respiratory infections in the United States each year, the extent of these severe adverse events is significant," said Dr. Carmichael. Researchers also found that the antibiotic Cefdinir was the fourth most prescribed antibiotic for these patients, despite it rarely being recommended by prescription guidelines as an appropriate treatment for simple upper respiratory infections. This drug also had the second highest chance of leading to an adverse event. That means that patients are being prescribed a medication that is either not needed at all or unlikely to be the most appropriate medication for their condition and is routinely causing harm, said Dr. Carmichael. He added that the chance of adverse events is likely much higher, as these results only capture follow-up visits where their adverse event was coded as such for insurance purposes. That means the results do not include adverse events where physicians didn't code for that specific side effect, nor for patients who weren't sick enough to be seen in a doctor's office but may still have had additional and unnecessary time for recovery. These findings point to the increasingly important need for antibiotic stewardship programs, so that physicians are following prescribing guidelines and "only prescribe antibiotics when necessary, and then it's the right antibiotics for the right condition," said Dr. Carmichael. When Intermountain implemented their own enhanced antibiotic stewardship programs, which included explaining to patients why they weren't being prescribed an antibiotic if they asked for it, the health system reduced their overall prescribing rates by more than 15%. "Patients don't get upset when they don't get antibiotics, as long as we take the time to explain their condition and that we're treating them in the way that is best for them," said Dr. Carmichael.

Clinical Result

100 Deals associated with Cefdinir

External Link

KEGG	Wiki	ATC	Drug Bank
D00917	Cefdinir	J01DD15	DB00535

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bronchitis	JP	LTL Pharma Co., Ltd.	27 Apr 2017
Cystitis	JP	LTL Pharma Co., Ltd.	27 Apr 2017
Otitis Media	JP	LTL Pharma Co., Ltd.	27 Apr 2017
Pneumonia, Bacterial	JP	LTL Pharma Co., Ltd.	27 Apr 2017
Sinusitis	JP	LTL Pharma Co., Ltd.	27 Apr 2017
Skin Diseases, Bacterial	JP	LTL Pharma Co., Ltd.	27 Apr 2017
Bacterial Infections	CN	Fujisawa Pharmaceutical Co., Ltd.	21 Apr 1999
Acute maxillary sinusitis	US	AbbVie, Inc.	04 Dec 1997
Bacterial otitis media	US	AbbVie, Inc.	04 Dec 1997
Bronchitis, Chronic	US	AbbVie, Inc.	04 Dec 1997
Community Acquired Pneumonia	US	AbbVie, Inc.	04 Dec 1997
Non-complicated skin and skin structure infection	US	AbbVie, Inc.	04 Dec 1997
Tonsillitis	US	AbbVie, Inc.	04 Dec 1997
Gram-Negative Bacterial Infections	-	-	01 Jan 1991
Gram-Positive Bacterial Infections	-	-	01 Jan 1991

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute otitis media	Phase 3	US	Abbott Laboratories	01 Jul 2002
Acute otitis media	Phase 3	CL	Abbott Laboratories	01 Jul 2002
Acute otitis media	Phase 3	CR	Abbott Laboratories	01 Jul 2002
Acute otitis media	Phase 3	DO	Abbott Laboratories	01 Jul 2002
Acute otitis media	Phase 3	GT	Abbott Laboratories	01 Jul 2002
Acute otitis media	Phase 3	IL	Abbott Laboratories	01 Jul 2002
Acute otitis media	Phase 3	PA	Abbott Laboratories	01 Jul 2002
Acute Bronchitis	Phase 1	CN	Shenzhen Zhijun Pharmaceutical Trade Co., Ltd.	24 Mar 2013
Adnexitis	Phase 1	CN	Shenzhen Zhijun Pharmaceutical Trade Co., Ltd.	24 Mar 2013
Blepharitis	Phase 1	CN	Shenzhen Zhijun Pharmaceutical Trade Co., Ltd.	24 Mar 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02891915 (CTgov)	Phase 4	Community Acquired Pneumonia \| Cataract Anterior Polar Dominant	385	aminopenicillin+clavulanate+amoxicillin trihydrate+Cefdinir (Short Course)	czmmhwtihc(nqimqmroor): Pr (Higher DOOR in Short-Course) = 0.69 (95% CI, 0.63 - 0.75), P-Value = <0.001 View more	-	03 Feb 2021
				aminopenicillin+clavulanate+amoxicillin trihydrate+Amoxicillin-Clavulanate+Cefdinir (Standard Course)
NCT00834535 (CTgov)	Phase 1	-	32	Cefdinir (Cefdinir (Test))	okwqgnzcfe(rpmjhfvkuz) = xcvqctuxfx pwdwdmvfqu (ntyziecoyp, fqmjudafpt - scaolrlaxo) View more	-	21 Jul 2009
				Omnicef (Omnicef® (Reference))	okwqgnzcfe(rpmjhfvkuz) = lpcglialos pwdwdmvfqu (ntyziecoyp, zmbibrdtet - yhptscgwgh) View more
NCT00835549 (CTgov)	Phase 1	-	32	Cefdinir (Cefdinir (Test))	lqahhztzmc(klsfzkhraq) = phafyrcjbl obqqjhlpgo (qfwpogjyid, djxuwwzogi - jbgpqicsdv) View more	-	21 Jul 2009
				Omnicef (Omnicef® (Reference))	lqahhztzmc(klsfzkhraq) = uzdgpytbki obqqjhlpgo (qfwpogjyid, ogffscvadb - iwihihxfpd) View more
NCT00835484 (CTgov)	Phase 1	-	32	Cefdinir (Cefdinir (Test))	utawaldups(vtprdaanjq) = ftrkxinryc agjjtldvtk (fwbtiikdhl, zcrrijdgiq - pdyxgexqjj) View more	-	21 Jul 2009
				Omnicef (Omnicef® (Reference))	utawaldups(vtprdaanjq) = vdxbisbryw agjjtldvtk (fwbtiikdhl, ntdcnhziaq - ajmmufcivj) View more
NCT00834574 (CTgov)	Phase 1	-	32	Cefdinir (Cefdinir (Test))	tgfcjzrzmr(zkxdofdosj) = kmilgvpsmw wzekmzekjn (gpxyflsvwj, liahqopkvt - rppfyianxu) View more	-	21 Jul 2009
				Omnicef (Omnicef® (Reference))	tgfcjzrzmr(zkxdofdosj) = fjkhrypwxc wzekmzekjn (gpxyflsvwj, ugyvnlccqk - tdisauhppp) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis